A New Approval: The SMA Treatment Landscape

Welcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

    

In this episode, we spoke with Richard Finkel, MD, a pediatric neurologist and recently named head of the new Center for Experimental Neurotherapeutics at St. Jude Children’s Research Hospital. Finkel offered an in-depth look at how the recent FDA approval of oral risdiplam (Evrysdi; Roche) might impact the spinal muscular atrophy (SMA) therapeutic landscape.

Thanks for listening to the NeurologyLive Mind Moments podcast. For more neurology news and expert-driven content, visit neurologylive.com.